The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial - Nature Medicine In this phase 2, randomized trial in early Alzheimer’s disease, the TREM2 agonistic antibody AL002 showed target engagement but did not meet the primary endpoint of change from baseline in Clinical De...

Results from the #INVOKE2 phase 2 trial of the #TREM2 agonistic #antibody #AL002 in early #Alzheimers disease out now. Although #AL002 showed target engagement, no change in CDR-SB was seen. #microglia #dementia #AD
www.nature.com/articles/s41...

Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks - Nature Medicine Plasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimerʼs disease.

Study out in @naturemedicine.bsky.social describes the development of a plasma #ptau217-based #clock that allows researchers to predict when cognitively unimpaired individuals may develop symptoms of #Alzheimers disease. #AD #AD_Biomarkers
www.nature.com/articles/s41...

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial - Nature Medicine A single intravenous dose of the psychedelic dimethyltryptamine, combined with psychological support, produces rapid and lasting reductions in depressive symptoms in adults with major depressive disor...

A single intravenous dose of the #psychedelic #DMT, combined with psychological support, produces rapid and lasting reductions in depressive symptoms in adults with major depressive disorder. #Depression #MDD
www.nature.com/articles/s41...

Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide - Nature Medicine This study provides the first evidence in humans that tirzepatide modulates brain electrophysiology, with changes in low-frequency accumbens power linked to food preoccupation.

🌟New study just out in @natmed.nature.com reports a first-in-human exploration of the #electrophysiological action of #tirzepatide in the #brain, where they observe changes in low frequency accumbens power associated with #food #cravings. #GLP1
www.nature.com/articles/s41...

Serum proteomics in people with pre-symptomatic #MultipleSclerosis reveals #myelin damage up to 7 years before symptoms—preceding axonal injury by ~1yr. #Astrocyte involvement emerges only at clinical onset. #MS
www.nature.com/articles/s41...

Characterizing the physiology of circulatory arrest in humans - Nature Medicine The authors conducted prospective multimodal monitoring of simultaneous brain and heart function to define physiological changes during the human dying process leading to circulatory arrest.

A new paper out in @natmed.nature.com provides a prospective multimodal assessment of simultaneous #cerebrovascular and #cardiovascular physiology of the human dying process until #circulatory arrest. @mypster.bsky.social @cerebriubc.bsky.social
www.nature.com/articles/s41...

The astrocytic ensemble acts as a multiday trace to stabilize memory - Nature Emotional experience evokes signalling in astrocytes, which form an ensemble that is reinforced by secondary astrocytic state changes resulting from repeated experience, leading to memory stabilizatio...

Nice study in @nature.com that identifies #astrocytic ensembles that link experiences across days to stabilize #memory. #astrocytes #glia
www.nature.com/articles/s41...

An illustration of me, and the headline: "AI agents are coming for your privacy, warns Meredith Whittaker The Signal Foundation’s president worries they will also blunt competition and undermine cyber-security"

To put it bluntly, the path currently being taken towards agentic AI leads to an elimination of privacy and security at the application layer. It will not be possible for apps like Signal—the messaging app whose foundation I run—to continue to provide strong privacy guarantees, built on robust and openly validated encryption, if device-makers and OS developers insist on puncturing the metaphoric blood-brain barrier between apps and the OS. Feeding your sensitive Signal messages into an undifferentiated data slurry connected to cloud servers in service of their AI-agent aspirations is a dangerous abdication of responsibility.

Happily, it’s not too late. There is much that can still be done, particularly when it comes to protecting the sanctity of private data. What’s needed is a fundamental shift in how we approach the development and deployment of AI agents. First, privacy must be the default, and control must remain in the hands of application developers exercising agency on behalf of their users. Developers need the ability to designate applications as “sensitive” and mark them as off-limits to agents, at the OS level and otherwise. This cannot be a convoluted workaround buried in settings; it must be a straightforward, well-documented mechanism (similar to Global Privacy Control) that blocks an agent from accessing our data or taking actions within an app. Second, radical transparency must be the norm. Vague assurances and marketing-speak are no longer acceptable. OS vendors have an obligation to be clear and precise about their architecture and what data their AI agents are accessing, how it is being used and the measures in place to protect it.

📣 NEW -- In The Economist, discussing the privacy perils of AI agents and what AI companies and operating systems need to do--NOW--to protect Signal and much else!

www.economist.com/by-invitatio...

Varicella-zoster virus reactivation and the risk of dementia - Nature Medicine Large-scale longitudinal health records reveal consistent association of varicella-zoster virus reactivation with dementia.

New study out in @naturemedicine.bsky.social reveals a relationship between #VaricellaZoster #virus reactivation and risk of #dementia in a large, diverse US database. #Shingles #VZV
www.nature.com/articles/s41...

A phase 3 trial found that VER-01, a full-spectrum #cannabis extract, reduces chronic low #BackPain, improves function and sleep, and shows no signs of dependence or withdrawal. #ChronicPain, #LowBackPain #ChronicPainRelief #PainRelief
https://www.nature.com/articles/s41591-025-03977-0

Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial - Nature Medicine A phase 3 trial found that VER-01, a full-spectrum cannabis extract, reduces chronic low back pain, improves physical function and sleep and shows no signs of dependence or withdrawal.

A new phase 3 trial found that VER-01, a full-spectrum #cannabis extract, reduces #Chronic #LowBackPain, improves function and #sleep, and shows no signs of #dependence or #withdrawal. #Pain #ChronicPain
www.nature.com/articles/s41...

Check out #February's Editorial in @NatureMedicine highlighting the potential of #DementiaPrevention approaches to combat the rising incidence of #dementia and the need for more #ClinicalTrials. #Alzheimers #AD #Prevention #Aging
http://dlvr.it/TJ5FXF

Prenatal #CellFreeDNA screening enables the detection of early placental and endothelial-tissue aberrations and may aid in the determination of #preeclampsia risk. #EarlyDetection #MaternalHealth #GeneticTesting
http://dlvr.it/THyPrd

Periodic cooking of eggs - Communications Engineering Emilia Di Lorenzo and colleagues propose the perfect way to boil an egg

Is any boiled egg 🥚 worth 32 minutes of work?? #Perfection #BoiledEggs #CulinaryTechnique
http://dlvr.it/THxMMD

Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia - Nature Medicine A rare case of asymptomatic dominantly inherited Alzheimer’s reveals confined tau pathology and unique proteomic features, highlighting potential resilience mechanisms decades beyond expected onset.

A rare case of asymptomatic dominantly inherited #Alzheimer's reveals confined tau pathology and unique proteomic features, highlighting potential resilience mechanisms decades beyond expected onset. #Resilience #Dementia
http://dlvr.it/THwPxY